Synageva BioPharma Corp

Most Recent

  • uploads///PLL DHR moat
    Miscellaneous

    MAC Clause: How the Circumstances Impact Pall

    A fire at one of Pall’s factories would be a MAC. If a major Pall customer left because they didn’t want to work with Danaher, it isn’t a MAC.

    By Brent Nyitray, CFA, MBA
  • uploads///PLL DHR industrial
    Miscellaneous

    MAC Clause: How Can Danaher Walk Away?

    The MAC clause has been paraphrased to limit the legalese. This part lays out the circumstances under which Danaher (DHR) can walk away from its deal with Pall (PLL).

    By Brent Nyitray, CFA, MBA
  • uploads///PLL DHR DHR basics
    Miscellaneous

    Pall-Danaher Transaction: What You Should Know about Danaher

    Danaher (DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services.

    By Brent Nyitray, CFA, MBA
  • uploads///PLL DHR Pall basics
    Miscellaneous

    Pall-Danaher Transaction: An Overview of Pall

    Pall (PLL) is a supplier of filtration, separation, and purification technologies. Pall divides its business segments into Life Sciences and Industrial.

    By Brent Nyitray, CFA, MBA
  • uploads///GEVA ALXN LAL D
    Miscellaneous

    Backing Out of the Synageva BioPharma Deal, Part 3

    Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.

    By Brent Nyitray, CFA, MBA
  • uploads///GEVA ALXN GEVA pipeline
    Miscellaneous

    Backing Out of the Synageva BioPharma Deal, Part 1

    In this case, the material adverse change clause lays out the circumstances under which Alexion could back out of its deal with Synageva. This clause is one of the first things that arbitrageurs look at.

    By Brent Nyitray, CFA, MBA
  • uploads///GEVA ALXN GEVA basics
    Miscellaneous

    Synageva BioPharma: A Pipeline of Therapeutic Programs

    Synageva has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

    By Brent Nyitray, CFA, MBA
  • uploads///GEVA ALXN Kanuma
    Miscellaneous

    Alexion Pharmaceuticals Would Benefit from Synageva Pipeline

    This deal is about buying a pipeline and intellectual property. Synageva Biopharma’s drug Kanuma is used for the treatment of LAL D, a childhood disease.

    By Brent Nyitray, CFA, MBA
  • uploads///GEVA ALXN strategy
    Miscellaneous

    The Synageva–Alexion Merger: Stock and Cash Considerations

    The Synageva–Alexion transaction is a merger involving cash and stock considerations. These deals have a longer time frame than cash-tender deals, which can close in as little as 45 days.

    By Brent Nyitray, CFA, MBA
  • uploads///GEVA ALXN spread
    Miscellaneous

    Alexion Pharmaceuticals Pays up to Get Synageva BioPharma

    The transaction’s risk-to-reward ratio explains why the spread is wide. In fact, it looks like Synageva has some good protections in the material adverse effect clause.

    By Brent Nyitray, CFA, MBA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.